Leukemia Research
Editorial
Iron overload, cardiac iron loading and function in myelodysplastic syndrome (Available online 4 February 2009)
"The article by Kazuma Ohyashiki and colleagues published in this
issue of Leukemia Research is a relevant contribution in this
setting being the first attempt to study this complex network of effects
and correlations in MDS patients."
by Emanuele Angelucci, Anna Angela Di Tucci |
|
研究内容紹介
■ 20008年[PDＦ] 学会発表も入っています。
■ 2007年[PDF]
■ 2006年[PDF]
■ 2005年[PDF]
2009年
Ohyashiki JH, Hisatomi H, Shimizu S, Sugaya M, Ohyashiki K: Detection of
low allele burden of JAK2 exon 12 mutations using TA-cloning in patients
with erythrocytosis. Japanese Journal of Clinical Oncology, 2009, in press.
Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T,
Ohyashiki K: Anti-proliferative activity of heat shock protein (Hsp) 90
inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Cancer Letters, 2009 in press.
Kitahara T, Gotoh M, Toyotake J, Akahane D, Ohyashiki K: Recurrent diffuse
large B-cell lymphoma (DLBCL) in the spinal cord detected by [18F] fluoro-deoxyglucose
([18F])FDG) positron emission tomography/ computed tomography (FDG-PET/CT).
Hematology.com, 2008, in press.
Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K: Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leukemia Research, 2009, 33:506-508.
Eguchi-Ishimae M, Eguchi M, Ohyashiki K, Yamagata T, Mitani K: enhanced
expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells. International Journal of Hematology, 2009, 89: 253-256.
Park J, Ohyashiki K, Akata S, Tanaka K, Uno R, Kakizaki D, Miyazawa K, Kimura Y, Tokuue K: Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging. Leukemia Research, 2009, 33:756-758.
Okabe S, Tauchi T, Ohyashiki JH, Ohyashiki K: Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochemical and Biophysical Research Communications, 2009, 380:775-779.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K,
Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford
S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori
H, Naoe T: A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant
or ?intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International Journal of Hematology, 2009, 89:679-688.
Kiguchi T, Ito Y, Kimura Y, Ohyashiki K: Restoration of cardiac function
by an iron chelation therapy with deferasirox in a patient with aplastic
anemia and cardiac iron overload. International Journal of Hematology, 2009, 89: 546-548.
Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki JH, Ohyashiki K, Kuroda M: Down-regulation of miR-92a in human plasma is a novel marker for acute leukemia patients. Plos ONE, 4:e5532.
Ohyashiki JH, Kobayashi C, Hamamura RS, Okabe S, Tauchi T, Ohyashiki K:
The oral chelator deferasirox represses signaling through the mTOR in myeloid
leukemia cells by enhancing expression of REDD1. Cancer Science, 2009, 100: 970-977.
Kawakami H, Tsuchida A, Miyazawa K, Naito M, Shigoka M, Kyo B, Enomoto
M, Wada T, Katsumata K, Ohyashiki K, Ito M, Tomoda A, Aoki T: Growth inhibitory
effects of vitamin K2 on colon cancer cell lines via different types of
cell death including autophagy and apoptosis. International Journal of Molecular Medicine, 2009, 23:709-716.
2008年
1. Okabe S, Tauchi T, Broxmeyer H, Ohyashiki K: Characterization of Dasatinib-
and Imatinib-resistant chronic myelogenous leukemia cells. Clinical Cancer Research, 2008, 14: 6181-6186.
2. Akahane D, Tauchi T, Okabe S, Nunoda K, Ohyashiki K: Activity of a novel
aurora kinase inhibitor against T315I mutation form of BCR-ABL in vitro
and in vivo studies. Cancer Science, 2008, 29:1251-1257.
3. Yokoyama T, Miyazawa K, Naito M, Toyotake J, Tauchi T, Ito M, Yuo A,
Kondo Y, Kondo S, Ohyashiki K: Vitamin K2 induced autophagy and apoptosis
simultaneously in leukemia cells and Bcl-2 expression level determines
the phenotype of their cell death. Autophagy, 2008, 4:629-640.
4. Ohyashiki K, Kiguchi T, Ito Y, Gotoh A, Tauchi T, Miyazawa K, Kimura
Y, Hisatomi H, Ohyashiki JH: Isolated erythrocythemia: A distinct entity
or a sub-type of polycythemia vera ? Japanese Journal of Clinical Oncology, 2008, 38:230-232.
5. Ohyashiki K, Kodama A, Ohyashiki JH: Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly lined to myelofibrosis development. Cancer Genetics and Cytogenetics 2008, 186:6-11
6. Tamai H, Yamaguchi H, Hamaguchi H, Yagasaki F, Bessho M, Kobayashi T,
Akiyama H, Sakamaki H, Takahashi S, Tojo A, Ohmine K, Ozawa K, Okumura
H, Nakao S, Arai A, Miura O, Toyoda S, Gomi S, Murai Y, Usui N, Miyazawa
K, Ohyashiki K, Takahashi N, Sawada K, Kato A, Oshimi K, Inokuchi K, Dan
K. Clinical features of adult acute leukemia with 11q23 abnormalities in
Japan: multicenter co-operative study. International Journal of Hematology, 2008, 87:195-202.
7. Ohyashiki K, Kiguchi T, Ito Y, Gotoh A, Tauchi T, Miyazawa K, Kimura
Y, Ohyashiki JH: Leukocytosis is linked to thrombosis at diagnosis, while
JAK2 V617F mutation is associated with thrombosis during the course of
essential thrombocythemia. International Journal of Hematology, 2008, 87:446-448.
8. Miyazawa K, Ohyashiki K, Urabe A, Hara T, Nakao S, Takatoku M, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Hattori T, Taniguchi J, Tanii H, Omine M: A Phase I, safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL 670) in Japanese patients with rare anemias and transfusional iron overload. International Journal of Hematology, 2008, 88:73-81.
9. Akahane D, Ito Y, Sumi M, Tauchi T, Kimura Y, Ohyashiki K: Relapse of
chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic
stem cell transplantation. International Journal of Hematology, 2008, 88:1198-120.
10. Gotoh M, Sasaki Y, Iguchi T, Fujimoto H, Kiyoi H, Naoe T, Ohyashiki
K: Karyotypically independent trisomy 10 and del(11q) in acute myeloid
leukemia. International Journal of Hematology, 2008, 88: 123-124.
11. Tauchi T, Ohyashiki JH, Ohyashiki K: Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. Methods Molecular Biology. 2008; 405: 181-189.
12. Kanda Y, Okamoto S, Tauchi T, Kizaki M, Inokuchi K, Yabe M, Yokoyama
K, Ito Y, Kimura Y, Higashihara M, Bessho M, Ando K, Chiba S, Kurokawa
M, Oshimi K, Dan K, Ohyashiki K, Ikeda Y for the Tokyo STI Study Group:
Multicenter prospective trial to evaluate the tolerability of imatinib
at 400 mg daily for Japanese patients with chronic myelogenous leukemia
in chronic phase. Does body weight matter? American Journal of Hematology, 2008, 83:835-839.
13. Bennett JM for the MDS Foundation’s Working Group on Transfusion Iron Overload (contributors, Ohyashiki K, et al): Consensus statement on iron overload in myelodysplastic syndromes. American Journal of Hematology, 2008, 83:858-861.
14. Slovak ML, Dewald GW: International Working Group on MDS cytogenetics:
October 2007 meeting report (contributors, Ohyashiki K, et al.). Leukemia Research, 2008, 32: 1329-1332
15. Suzuki T, Tomonaga M, Miyazaki Y, Nakao S, Ohyashiki K, Matsumura I,
Kohgo Y, Niitsu Y, Kojima S, Ozawa K: Japanese epidemiological survey with
consensus statement of Japanese guidelines for treatment of iron overload
in bone marrow failure syndromes. International Journal of Hematology, 2008, 88: 30-35.
16. Ohyashiki JH, Ohyashiki K: Diagnostic and prognostic markers in hematologic neoplasia. 2008, in press.
17. Katagiri S, Akahane D, Yoshizawa S, Kiguchi T, Gotoh M, Tauchi T, Kimura
Y, Ohyashiki K: Bone marrow sarcoidosis in a patient with diffuse large
B cell lymphoma. BloodMed, 2008. slide atlas (2008/Nov).
18. Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K: A network approach for anti-cancer effect of bortezmib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Computational Biology and Chemistry: Advances and Applications, 2008, 1:85-98.
19. Hansson M, Zendehrokh N, Ohyashiki J, Ohyashiki K, Westman UB, Roos
G, Dejmek A. Telomerase activity in effusions: a comparison between telomere
repeat amplification protocol in situ and conventional telomere repeat
amplification protocol assay. Archive of Pathoogy and Laboratory Medicine. 2008 132:1896-902.
20. Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T, Kanamaru A, Okamoto S, Karasawa M, Kimura A, Tomonaga M, Uchiyama T, Ozawa K; Japanese Cooperative Study Group for Intractable Bone Marrow Diseases. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia 2008 22:1874-1881.
|
